Michael A. James

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

M. Raymond V. Finlay, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2014 · 590 citations · Full text

Genetics, Pathology, Clinical Candidate +18

Principles for the post-GWAS functional characterization of cancer risk loci

Matthew L. Freedman, Álvaro N.A. Monteiro, Simon A. Gayther et al. · Nature Genetics · 2011 · 454 citations

Genome-wide Association Study, Cancer Risk, Cancer Epidemiology +12

Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models

Susan Tsai, Laura McOlash, Katie Palen et al. · BMC Cancer · 2018 · 372 citations · Full text

Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing

Pengyuan Liu, Carl Morrison, Liang Wang et al. · Carcinogenesis · 2012 · 205 citations · Full text

Human Papillomavirus Type 16 E6 Activates NF-κB, Induces cIAP-2 Expression, and Protects against Apoptosis in a PDZ Binding Motif-Dependent Manner

Michael A. James, John H. Lee, Aloysius J. Klingelhutz · Journal of Virology · 2006 · 151 citations · Full text

Apoptosis, Immunology, Pathology +18